• Vaccine Ontology ID: VO_0004389
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• GP from Musoke Marburgvirus gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector rAd type 5 (rAd5) expressed GP of MARV (Geisbert et al., 2010).
  • Detailed Gene Information: Click Here.
• Vector: CMV/R and rAd type 5 (rAd5) (Geisbert et al., 2010)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004390
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• GP from Musoke Marburgvirus gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector CMV/R expressed GP of MARV (Geisbert et al., 2010).
  • Detailed Gene Information: Click Here.
• Vector: CMV/R (Geisbert et al., 2010)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004387
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse, rabbit, guinea pig
• GP from Marburg virus Ravn gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pWRG7077 expressed MARV Musoke GP in challenge study with macaques (Riemenschneider et al., 2003).
  • Detailed Gene Information: Click Here.
• Vector: pWRG7077 (Riemenschneider et al., 2003)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011394
• Type: Recombinant vector vaccine
• Status: Research
• NP from Lake Victoria marburgvirus gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: An RNA replicon, based upon Venezuelan equine encephalitis (VEE) virus, was used as a vaccine vector (Hevey et al., 1998).
• Immunization Route: Subcutaneous injection

• Vaccine Ontology ID: VO_0004388
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant vector construction
  • Description: This DNA vaccine expressed MARV Musoke GP (Swenson et al., 2008).
  • Detailed Gene Information: Click Here.
• NP from Marburg virus Musoke gene engineering:
  • Type: Recombinant vector construction
  • Description: This DNA vaccine expressed MARV Musoke NP (Swenson et al., 2008).
  • Detailed Gene Information: Click Here.
• GP from Marburg virus Ci67 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• GP from Marburg virus Ravn gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• NP gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• GP gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• SGP gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Vector: CAdVax (Swenson et al., 2008)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004391
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Guinea pig, macaques
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant vector construction
  • Description: Vector Venezuelan equine encephalitis (VEE) virus expressed the gene for MBGV GP (Hevey et al., 1998).
  • Detailed Gene Information: Click Here.
• Vector: Venezuelan equine encephalitis (VEE) virus (Hevey et al., 1998)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004566
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Guinea pig, macaques
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• NP from Marburg virus Musoke gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Vector: Venezuelan equine encephalitis (VEE) virus (Hevey et al., 1998)
• Immunization Route: subcutaneous injection

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: The vaccine induced humoral responses , as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP. The highest antibody titers were achieved with a heterologous prime-boost vaccine. rAd5-GP boosted titers in DNA-primed animals more than 2 orders of magnitude to a final prechallenge GP ELISA IgG titer of 1:237,167 (Geisbert et al., 2010).
• Efficacy: Heterologous prime-boost with DNA/rAd vectors generated protective immunity in all subjects after challenge with a lethal dose of MARV Angola (Geisbert et al., 2010).

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: The DNA/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP (Geisbert et al., 2010).
• Efficacy: The DNA-GP-only vaccine prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola (Geisbert et al., 2010).

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: All of the MARV GP DNA-vaccinated guinea pigs developed antibodies to MARV (Riemenschneider et al., 2003).
• Efficacy: In both studies (two different strains - Musoke and Ravn), two of three GP DNA-vaccinated monkeys were aviremic on the days assayed, and survived challenge, while one monkey in each study developed viremia levels similar to those of control monkeys and died. These results indicate that DNA vaccination alone is able to offer immunity to nonhuman primates, but suggest that the protective effect is near the threshold of vaccine efficacy (Riemenschneider et al., 2003).

Macaque Response

• Host Strain: Macaca fascicularis
• Vaccination Protocol: Twelve cynomolgus macaques (Macaca fascicularis), 11 females and 1 male, ranging from 2.8 to 4.5 kg, were inoculated subcutaneously with 10^7 FFU of VRP in a total volume of 0.5 ml at one site. Monkeys were anesthetized with ketamine, bled, and inoculated (as described for the first vaccine dose) 28 days after the primary injection, and again 28 days after the second (Hevey et al., 1998).
• Challenge Protocol: Animals were challenged 14 days after 3rd vaccine dose with 10^3.9 PFU MBGV
  subcutaneously (Hevey et al., 1998).
• Efficacy: MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques (Hevey et al., 1998).

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: All vaccinated animals from groups 1(challenged with 1,000 PFU MARV Musoke) and 2 (challenged with the same dose of ZEBOV) mounted strong antibody titers against all five filoviruses with similar kinetics (Swenson et al., 2005).
• Efficacy: Vaccination of NHP with CAdVax-Panfilo was 100% protective against challenge with multiple filovirus species, including ZEBOV, SEBOV, MARV Musoke, and MARV Ci67 (Swenson et al., 2005).

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease (Hevey et al., 1998).

Macaque Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease (Hevey et al., 1998).